<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03590886</url>
  </required_header>
  <id_info>
    <org_study_id>UDCA20181123</org_study_id>
    <nct_id>NCT03590886</nct_id>
  </id_info>
  <brief_title>Gut Microbes and Metabolic Group in Different PBC Patients for UDCA Response</brief_title>
  <official_title>A Clinical Study About Gut Microbes and Metabolic Group in Different PBC Patients for UDCA Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare intestinal flora diversity in different PBC patients with UDCA responses, and
      further study the differences of bile acid metabolism and short chain fatty acid metabolism
      in feces and serum of two groups of PBC patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PBC patients have been enrolled in the study for UDCA treatment more than 1 year, who is
      divided into the UDCA total response Group and the other poor response group according to
      Paris-I/II standard .The feces of two groups of patients were collected and the differences
      of microbial polymorphism of fecal microorganism in two groups were observed. The metabolic
      differences of bile acids and short chain fatty acids in serum and feces of two groups of PBC
      patients were studied by means of metabolic proteomics.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 22, 2018</start_date>
  <completion_date type="Actual">February 28, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>5 Months</target_duration>
  <primary_outcome>
    <measure>fecal microbial diversity</measure>
    <time_frame>6 months</time_frame>
    <description>Macrogenomic examination of fecal microbial DNA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>bile acid metabolites</measure>
    <time_frame>6 months</time_frame>
    <description>The examination of bile acid metabolites by ELISA methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>short chain fatty acid metabolites</measure>
    <time_frame>6 months</time_frame>
    <description>The examination of short chain fatty metabolites by ELISA methods</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Primary Biliary Cirrhosis</condition>
  <arm_group>
    <arm_group_label>total response Group</arm_group_label>
    <description>The PBC patients show biochemical response for UDCA treatment more than 1 year according to Paris-I/II standard</description>
  </arm_group>
  <arm_group>
    <arm_group_label>poor response group</arm_group_label>
    <description>The PBC patients show poor biochemical response for UDCA treatment more than 1 year according to Paris-I/II standard</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>total response Group</intervention_name>
    <description>biochemical response for UDCA treatment more than 1 year according to Paris-I/II standard</description>
    <arm_group_label>total response Group</arm_group_label>
    <other_name>poor response group</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Primary biliary cholangitis patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.Confirmed diagnostic criteria about PBC, and orally UDCA treatment for more than a year;
        2.30-70 years old; 3.Currently only UDCA therapy, not glucocorticoids and immunosuppressor
        treatment.

        Exclusion Criteria:

          1. Viral liver disease;

          2. alcoholic liver disease;

          3. fatty liver;

          4. drug-associated liver damage;

          5. infectious disease;

          6. obesity;

          7. gastrointestinal diseases;

          8. combined with other autoimmune diseases;

          9. cardiac and pulmonary dysfunction;

         10. renal dysfunction, malignant tumor,;

         11. neurological and psychiatric abnormalities;

         12. nearly 2 months to take antibiotics and probiotics;

         13. nearly 3 months participate in other drug clinical trials .
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin B Liang, MD</last_name>
    <role>Study Director</role>
    <affiliation>Third Affliated Hospital of Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>June 27, 2018</study_first_submitted>
  <study_first_submitted_qc>July 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2018</study_first_posted>
  <last_update_submitted>December 23, 2019</last_update_submitted>
  <last_update_submitted_qc>December 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Lin Bingliang</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

